SCHEMBL6079308

SCHEMBL6079308

O=C(Nc1ccc(F)c(COc2cnccn2)c1)Oc1cccc(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
ALOX15 P16050 1/20 0.41
CASP1 P29466 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GAA P10253 2/20 0.41
BRAF P15056 3/20 0.40
KDR P35968 2/20 0.40
MAPK14 Q16539 2/20 0.40
TNNI3K Q59H18 2/20 0.40
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HSP90AA1 P07900 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
P2RY1 P47900 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6250838 0.83 P2RY1 (0.45) NTRK1MEN1KMT2ATSHRNPSR1
SCHEMBL6079858 0.79 SYK (0.45) KMT2A
SCHEMBL6078849 0.77 BRAF (0.48) MEN1KMT2ATSHRNPSR1ALOX15
SCHEMBL6079788 0.75 MEN1 (0.52) MEN1KMT2A
SCHEMBL6079886 0.74 RAB9A (0.51) MEN1KMT2APOLBMAPTRAB9A
SCHEMBL6079669 0.74 HDAC3 (0.43) MEN1KMT2ABRAFMAPK14MAPT
SCHEMBL6079543 0.72 KMT2A (0.49) MEN1KMT2APOLBRAB9ANPC1
SCHEMBL6206878 0.71 RAF1 (0.39) NTRK1GAABRAFKDRMAPK14
SCHEMBL6080568 0.70 KMT2A (0.48) MEN1KMT2APOLBGAABRAF
SCHEMBL28209722 0.69 KMT2A (0.62) MEN1KMT2AGAAMAPTP2RY1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063782-A1 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2006-03-23 US disclosed
EP-1545523-A1 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS Astex Technology Limited (GB) 2005-06-29 EP disclosed
WO-2005002673-A1 RAF KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2005-01-13 WO disclosed
WO-2004004720-A1 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS ASTEX TECHNOLOGY LIMITED (GB) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063782-A1 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors MAPK1, MAPK3, MAPK10 NTRK1 227/4885MEN1 4610/4885KMT2A 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.